Halogen-substituted heterocyclic compound
US-2015376160-A1 · Dec 31, 2015 · US
Sulfonamides as TRPM8 modulators
US9434711B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9434711-B2 |
| Application number | US-201414322554-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 2, 2014 |
| Priority date | Jul 18, 2007 |
| Publication date | Sep 6, 2016 |
| Grant date | Sep 6, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein A, B, G, Y, R 1 , R 2 , R 3 , and R 4 are defined herein.
First claim
Opening claim text (preview).
We claim: 1. A method of treating inflammatory pain in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of: N-(3-Methyl-benzo[b]thiophen-2-yl)-N-(4-fluoro-3-trifluoromethyl-benzyl)-4-carboxy-benzenesulfonamide; N-(3-Methyl-benzo[b]thiophen-2-yl)-N-(4-trifluoromethoxy-benzyl)-4-carboxy-benzenesulfonamide; and N-(4-Fluoro-3-trifluoromethylbenzyl)-N-(3-(1-hydroxy-1-methyl-ethyl)-benzo[b]thiophen-2-yl)-4-carboxy-benzenesulfonamide. 2. The method of claim 1 wherein the inflammatory pain is due to inflammatory bowel disease, visceral pain, migraine, post operative pain, osteoarthritis, rheumatoid arthritis, back pain, lower back pain, joint pain, abdominal pain, chest pain, labor, musculoskeletal diseases, skin diseases, toothache, pyresis, burn, sunburn, snake bite, venomous snake bite, spider bite, insect sting, neurogenic bladder, interstitial cystitis, urinary tract infection, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, pharyngitis, mucositis, enteritis, irritable bowel syndrome, cholecystitis, pancreatitis, postmastectomy pain syndrome, menstrual pain, endometriosis, sinus headache, tension headache, or arachnoiditis.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9434711B2 cover?
- Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein A, B, G, Y, R 1 , R 2 , R 3 , and R 4 are defined herein.
- Who is the assignee on this patent?
- Janssen Pharmaceutica Nv, Janssen Pharmaceutica Nv
- What technology area does this patent fall under?
- Primary CPC classification C07D333/36. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).